Visiongain has published a new report on Tissue Diagnostics Market Report 2021-2031: Forecasts by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories. PLUS, Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS, COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/tissue-diagnostics-market-2021/#download_sampe_div
The growth of the market is attributed to the factors such as increase in healthcare spending and growing occurrence of cancer worldwide. A rise in the acceptance rate of automated tissue-based diagnostic systems by the research institutes empowers them to perform a faster diagnosis of tumours. For instance, in September 2019, West Clinic Cancer Centre affiliated with F. Hoffmann-La Roche Ltd. to enhance patient care by using Roche’s BenchMark ULTRA Automated Advanced Staining System. This system is used for in situ hybridization or immunohistochemistry testing to enable faster diagnosis of tumours.
COVID-19 Impact on Tissue Diagnostics Market
The rise in the pandemic of COViD-19 has affected all the industry globally. The impact of COViD-19 will influence the growth of the market positively. The tissue diagnostics product segment is used in the treatment of lung cancer diseases as well which also forms a common point of treatment for COViD patient so this will in-turn boost the market for the tissue diagnostics market.
Market Drivers
Tissue Diagnostics market is undergoing noteworthy growth rate due to the rising occurrence of cancer, developing infrastructure for cancer diagnosis, recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.
Driver 2
The tissue diagnostic market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to record the highest CAGR during the analysis period. This can primarily be attributed to the increasing incidence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.
Market Opportunities
Opportunity 1
The clinical trials market is growing owing to the increase in the number of cancer patients, thus increasing number of clinical trials pertaining to cancer drugs is paving the way for the growth for the tissue diagnostics market. Additionally, the tissue diagnostics also finds a huge demand in the developing nations specifically in BRICS countries of Brazil, Russia, India, China and South Africa.
Get Detailed TOC @ https://www.visiongain.com/report/tissue-diagnostics-market-2021/#download_sampe_div
Competitive Landscape
Some of the companies profiled in the report include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Qiagen (Germany), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), Dipath S.P.A. (Italy).
Recent Developments
- In 2019, Roche introduced the VENTANA PD-L1 (SP142) Assay in CE (Conformité Européenne) markets.
- In 2019, Hologic received CE approval for ThinPrep Genesis Processor.
- In 2019, Roche signed a contract with GE Healthcare to produce an integrated digital diagnostics platform to improve oncology and critical care treatment.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Tissue diagnostic market and leading companies. You will find data, trends and predictions.
Find more Visiongain research reports on Pharma Diagnostics Sector click on the following links:
- Biologics Market
- Cancer Diagnostics Market
- Ovarian Cancer Drugs Market
- Women's Health Diagnostics Market
- Companion Diagnostics (CDx) Market
- Cancer Supportive Care Drugs Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.
